NCT03663751View on ClinicalTrials.gov

Low-dose Decitabine for the Treatment of Decreased Donor Chimerism After Allogeneic Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

December 1, 2020

Study Completion Date

March 1, 2021

Conditions
Response Rate
Interventions
DRUG

Decitabine

low-dose decitabine: 5mg/m2 daily for 5 days

Trial Locations (1)

200025

Blood & Marrow Transplantation Center, RuiJin Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER

NCT03663751 - Low-dose Decitabine for the Treatment of Decreased Donor Chimerism After Allogeneic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter